Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 457,100 shares, a growth of 61.1% from the November 30th total of 283,800 shares. Based on an average trading volume of 350,200 shares, the days-to-cover ratio is presently 1.3 days. Approximately 17.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Trading Down 5.1 %

Shares of ALGS traded down $2.22 on Friday, reaching $41.15. 462,504 shares of the company’s stock were exchanged, compared to its average volume of 116,735. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $44.39. The stock has a market capitalization of $147.65 million, a P/E ratio of -3.09 and a beta of 2.71. The business has a 50 day moving average price of $21.55 and a two-hundred day moving average price of $15.03.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The company had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter in the prior year, the company posted ($10.25) EPS. Equities research analysts predict that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aligos Therapeutics stock. Armistice Capital LLC grew its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 5.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,256,410 shares of the company’s stock after acquiring an additional 363,000 shares during the quarter. Armistice Capital LLC owned 9.29% of Aligos Therapeutics worth $2,540,000 at the end of the most recent reporting period. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).